TP53 and glioblastoma: 29 was tested in human-derived glioblastoma models from patientswith either temozolomide resistance or sensitivity and either p53WT or mutant, with the most sensitive to 29 and ionizingradiation as expected being in the p53 mutant models, thus agreeingwith their previous data.